It has been suggested that phosphatidylcholine may improve intestinal barrier function21,22 and that an increased intestinal translocation of LPS leading to an activation of TLR4 and subsequently an activation of nuclear factor κ-light-chain enhancer of activated B cells (NFκB)-dependent signaling may be critical in the development of MASLD.7 The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.